In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Cardiff Oncology, with a price target of $10.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Robert Burns has given his Buy rating due to a combination of factors related to Cardiff Oncology’s recent clinical trial results and financial performance. The CRDF-004 trial data indicates that the combination of onvansertib with standard of care (SoC) achieved a higher confirmed overall response rate compared to the SoC alone, demonstrating promising efficacy despite a decline from initial results. Additionally, the unconfirmed response rate shows potential for further positive outcomes.
Cardiff’s financial results for the third quarter of 2025 showed a net loss per share that was better than anticipated, and the company maintains a strong cash position, which is expected to support operations into early 2027. The valuation of Cardiff Oncology is based on a discounted cash flow model, with a price target of $10 per share. However, risks such as potential negative trial results, delays in clinical advancements, and market penetration challenges are noted, but the overall outlook remains positive, justifying the Buy rating.
Burns covers the Healthcare sector, focusing on stocks such as Replimune Group, Cullinan Management, and Bicara Therapeutics Inc.. According to TipRanks, Burns has an average return of -2.6% and a 41.25% success rate on recommended stocks.